

AMENDMENTS TO THE CLAIMS

1-87. (canceled)

88. (currently amended) An isolated antibody or fragment thereof that specifically binds to a protein ~~having at least 90% homology to~~ comprising the amino acid sequence of SEQ ID NO: 728.

89. (previously presented) The antibody or fragment thereof of claim 88, wherein the antibody or fragment thereof is a monoclonal antibody.

90. (previously presented) The antibody or fragment thereof of claim 89, wherein the antibody is a human antibody, a humanized antibody or a chimeric antibody.

91. (previously presented) The antibody or fragment thereof of claim 88, wherein the fragment is an Fab, F(ab')₂, Fv or sFv fragment.

92. (previously presented) The antibody or fragment thereof of claim 88, wherein the antibody or fragment thereof is conjugated to an agent.

93. (previously presented) The antibody or fragment thereof of claim 92, wherein the agent is a diagnostic agent or a cytotoxic agent.

94. (previously presented) The antibody or fragment thereof of claim 93, wherein the cytotoxic agent is selected from the group consisting of radioactive isotopes, chemotherapeutic agents and toxins.

95. (previously presented) The antibody or fragment thereof of claim 94, wherein the radioactive isotope is selected from the group consisting of ²¹¹At, ¹³¹I, ¹²⁵I, ⁹⁰Y, ¹⁸⁶Re, ¹⁸⁸Re, ¹⁵³Sm, ²¹²Bi, ³²P and radioactive isotopes of Lu.

96. (previously presented) The antibody or fragment thereof of claim 94, wherein the chemotherapeutic agent is selected from the group consisting of taxol, actinomycin, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, gelonin, and calicheamicin.

97. (previously presented) The antibody or fragment thereof of claim 94, wherein the toxin is selected from the group consisting of diphtheria toxin, enomycin, phenomycin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, mitogellin, modeccin A chain, and alpha-sarcin.

98. (previously presented) The antibody or fragment thereof of claim 88, wherein the antibody or fragment thereof further comprises a pharmaceutically acceptable carrier.